Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report

Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that arise from secretory endocrine cells of the gastroenteropancreatic system. Clinical outcomes have improved for patients with GEP-NETs due to the development and recent FDA approval of (177)Lutetium DOTATATE. However,...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Vivian, Taparra, Kekoa, Fisher, George, Aparici, Carina, Soltys, Scott G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2023
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577096/
https://www.ncbi.nlm.nih.gov/pubmed/37849592
http://dx.doi.org/10.7759/cureus.45327
_version_ 1785121251004514304
author Zhang, Vivian
Taparra, Kekoa
Fisher, George
Aparici, Carina
Soltys, Scott G
author_facet Zhang, Vivian
Taparra, Kekoa
Fisher, George
Aparici, Carina
Soltys, Scott G
author_sort Zhang, Vivian
collection PubMed
description Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that arise from secretory endocrine cells of the gastroenteropancreatic system. Clinical outcomes have improved for patients with GEP-NETs due to the development and recent FDA approval of (177)Lutetium DOTATATE. However, the response of brain metastases from GEP-NETs from (177)Lutetium DOTATATE is unreported. We present the case of an 81-year-old man with low-grade small bowel GEP-NET with liver and brain metastases treated with a total of six cycles of (177)Lutetium DOTATATE. With over three years of follow-up from his initial treatment, his brain metastases have had complete or partial responses, with no need for brain radiotherapy or radiosurgery.
format Online
Article
Text
id pubmed-10577096
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Cureus
record_format MEDLINE/PubMed
spelling pubmed-105770962023-10-17 Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report Zhang, Vivian Taparra, Kekoa Fisher, George Aparici, Carina Soltys, Scott G Cureus Radiation Oncology Gastroenteropancreatic neuroendocrine tumors (GEP-NETs) are rare malignancies that arise from secretory endocrine cells of the gastroenteropancreatic system. Clinical outcomes have improved for patients with GEP-NETs due to the development and recent FDA approval of (177)Lutetium DOTATATE. However, the response of brain metastases from GEP-NETs from (177)Lutetium DOTATATE is unreported. We present the case of an 81-year-old man with low-grade small bowel GEP-NET with liver and brain metastases treated with a total of six cycles of (177)Lutetium DOTATATE. With over three years of follow-up from his initial treatment, his brain metastases have had complete or partial responses, with no need for brain radiotherapy or radiosurgery. Cureus 2023-09-15 /pmc/articles/PMC10577096/ /pubmed/37849592 http://dx.doi.org/10.7759/cureus.45327 Text en Copyright © 2023, Zhang et al. https://creativecommons.org/licenses/by/3.0/This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Radiation Oncology
Zhang, Vivian
Taparra, Kekoa
Fisher, George
Aparici, Carina
Soltys, Scott G
Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title_full Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title_fullStr Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title_full_unstemmed Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title_short Definitive Treatment of Brain Metastases From a Neuroendocrine Tumor With Peptide Receptor Radionuclide Therapy With 177Lutetium DOTATATE: A Case Report
title_sort definitive treatment of brain metastases from a neuroendocrine tumor with peptide receptor radionuclide therapy with 177lutetium dotatate: a case report
topic Radiation Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10577096/
https://www.ncbi.nlm.nih.gov/pubmed/37849592
http://dx.doi.org/10.7759/cureus.45327
work_keys_str_mv AT zhangvivian definitivetreatmentofbrainmetastasesfromaneuroendocrinetumorwithpeptidereceptorradionuclidetherapywith177lutetiumdotatateacasereport
AT taparrakekoa definitivetreatmentofbrainmetastasesfromaneuroendocrinetumorwithpeptidereceptorradionuclidetherapywith177lutetiumdotatateacasereport
AT fishergeorge definitivetreatmentofbrainmetastasesfromaneuroendocrinetumorwithpeptidereceptorradionuclidetherapywith177lutetiumdotatateacasereport
AT aparicicarina definitivetreatmentofbrainmetastasesfromaneuroendocrinetumorwithpeptidereceptorradionuclidetherapywith177lutetiumdotatateacasereport
AT soltysscottg definitivetreatmentofbrainmetastasesfromaneuroendocrinetumorwithpeptidereceptorradionuclidetherapywith177lutetiumdotatateacasereport

Ejemplares similares